Neuphoria Therapeutics Long Term Debt 2022-2025 | NEUP

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Neuphoria Therapeutics long term debt from 2022 to 2025. Long term debt can be defined as the sum of all long term debt fields.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Neuphoria Therapeutics long term debt from 2022 to 2025. Long term debt can be defined as the sum of all long term debt fields.

Related Stocks
Company Name	Market Cap
AstraZeneca (AZN)	$222.8B
Amgen (AMGN)	$162B
Gilead Sciences (GILD)	$140.6B
Vertex Pharmaceuticals (VRTX)	$118.3B
Bristol Myers Squibb (BMY)	$96.7B
CSL (CSLLY)	$85.2B
GSK (GSK)	$76.5B
Regeneron Pharmaceuticals (REGN)	$60.3B
Alnylam Pharmaceuticals (ALNY)	$42.3B
Argenex SE (ARGX)	$36.4B
BioNTech SE (BNTX)	$27.1B
Royalty Pharma (RPRX)	$20.8B
Insmed (INSM)	$19.3B
Biogen (BIIB)	$18.9B
Illumina (ILMN)	$17.4B
Genmab (GNMSF)	$15.2B
Genmab (GMAB)	$14.8B
Incyte (INCY)	$13.6B
Moderna (MRNA)	$13.1B
Exelixis (EXEL)	$12.1B
QIAGEN (QGEN)	$11.3B
BioMarin Pharmaceutical (BMRN)	$11.1B
Swedish Orphan Biovitrum (BIOVF)	$10.6B
Ascendis Pharma (ASND)	$10B
Bio-Techne Corp (TECH)	$9.2B
Exact Sciences (EXAS)	$9.1B
Verona Pharma American Depositary Share (VRNA)	$8.9B
Blueprint Medicines (BPMC)	$8.3B
Roivant Sciences (ROIV)	$7.7B
Legend Biotech (LEGN)	$7.6B